Important Disclaimer
This article is for educational and informational purposes only. Retatrutide is an investigational medication and has not been approved for use in the UK or any other country as of July 2026. The information below summarises publicly available data from clinical trials. It is not medical advice. Retatrutide should only be used in approved clinical trial settings under medical supervision. Always consult a qualified healthcare professional before considering any weight management treatment.
Overview of the TRIUMPH Clinical Trial Programme
Retatrutide is being studied in a large Phase 3 clinical trial programme called TRIUMPH. These studies are designed to evaluate the safety and effectiveness of retatrutide in people with obesity and related conditions.
The trials have examined different doses of retatrutide given once weekly by injection. Researchers have focused on weight loss, blood sugar control, and other health markers.
Key Results from the TRIUMPH Trials (2025–2026)
Several important readouts have been released so far:
- In one major study, participants taking the 12 mg dose lost an average of 28.3% of their starting body weight over 80 weeks.
- A notable percentage of participants achieved 30% or greater weight loss.
- Some individuals continued to lose weight beyond 80 weeks in extension phases of the trials.
- The medication also showed improvements in certain cardiovascular risk factors and blood sugar levels in people with type 2 diabetes.
These results are among the highest weight loss percentages reported in any medication studied for obesity to date.
How the Trials Were Designed
The TRIUMPH studies included thousands of participants across multiple countries. Key features of the trials include:
- Randomised, double-blind, placebo-controlled design
- Different dose levels tested (including 4 mg, 8 mg, and 12 mg)
- Gradual dose escalation to improve tolerability
- Treatment periods lasting up to 80 weeks or longer in some cases
- Regular monitoring of side effects and health markers
Participants followed structured lifestyle advice alongside the medication during the studies.
Weight Loss Results by Dose
Early data from the trials suggests a dose-dependent effect:
- Lower doses produced meaningful weight loss.
- Higher doses (particularly 12 mg) were associated with the greatest average reductions in body weight.
- Not all participants reached or tolerated the highest dose.
It is important to note that individual results varied, and weight loss was measured alongside diet and exercise support provided in the trials.
Other Health Outcomes Studied
In addition to weight loss, researchers looked at:
- Changes in waist circumference
- Improvements in blood sugar control (HbA1c)
- Effects on blood pressure and cholesterol levels
- Impact on sleep apnoea and joint pain in some study groups
These additional outcomes are still being analysed as more data becomes available.
Current Status of Retatrutide (July 2026)
Retatrutide remains an investigational treatment. As of now, it has not received regulatory approval from the MHRA in the UK or from other major agencies. Further trial results and regulatory review will determine whether it becomes available as a prescribed medication in the future.
Safety and Side Effects Observed in Trials
Common side effects reported during the studies included nausea, vomiting, diarrhoea, and decreased appetite. These effects were generally more noticeable when doses were increased. Some participants also experienced changes in heart rate.
Because retatrutide activates three hormone receptors, researchers continue to monitor its long-term safety profile carefully.
Strong Warning: Do not attempt to use retatrutide or similar peptides outside of clinical research settings. Unsupervised use can carry serious health risks.
What This Means for People in the UK
At present, retatrutide is not available through normal medical channels in the United Kingdom. People who are interested in weight management options should speak with their doctor about currently approved treatments.
Those conducting legitimate laboratory research may source research-grade peptides from specialist suppliers who clearly state that products are for research use only.
For a complete overview of retatrutide, read our main guide: [Retatrutide for Weight Management: Complete 2026 UK Guide](link to your pillar page).